Last reviewed · How we verify
Conventional strategy Aspirin
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation. Used for Acute myocardial infarction prevention and secondary prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.
At a glance
| Generic name | Conventional strategy Aspirin |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management; Inflammation |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, which is essential for platelet activation and clot formation, thereby reducing thrombotic events. Additionally, aspirin reduces prostaglandin-mediated inflammation and pain signaling.
Approved indications
- Acute myocardial infarction prevention and secondary prevention
- Ischemic stroke prevention
- Transient ischemic attack (TIA) prevention
- Unstable angina
- Mild to moderate pain and fever
- Rheumatoid arthritis and other inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Hemorrhagic stroke (at higher doses)
- Allergic reactions (including bronchospasm in aspirin-sensitive individuals)
- Renal impairment (chronic use)
Key clinical trials
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome (PHASE4)
- Ticagrelor De-escalation Strategy in AMI Patients (PHASE4)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4 (PHASE4)
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (PHASE2)
- Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional strategy Aspirin CI brief — competitive landscape report
- Conventional strategy Aspirin updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI